Frontlight ResearchEarly access
WithdrawnPhase 2
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
Key facts
- Who runs it
- John M. Buatti
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 15 May 2019
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- External beam radiation therapy
- Record updated
- 9 September 2020
- Why it stopped
- Not funded
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Ability to understand and willingness to provide informed consent
- Newly diagnosed, histologically-confirmed supratentorial WHO grade IV gliomas including glioblastoma (all variants) and gliosarcoma
- Patients must be 18 years of age or older.≥
- Karnofsky performance status ≥ 70
- Minimal life expectancy of 12 weeks
- Maximal contiguous volume of tumor based on high b-value diffusion MRI and perfusion MRI < 1/3 volume of brain
- Patients must be treated within 6 weeks of most recent resection; Within 21 days of radiation fraction 1, the following blood test parameters must be met:
- Hemoglobin ≥ 10 g/dL (transfusion is acceptable)
- absolute neutrophils ≥ 1500/mm3
- platelet count ≥ 100,000/mm3
- total bilirubin ≤ 2 x upper limit of normal (ULN) (unless elevated bilirubin is related to Gilbert syndrome)
- ALT and AST ≤ 5 x ULN
- serum creatinine ≤ 2.0 mg/dL
Who cannot take part
- Recurrent glioma, or tumor involving the brainstem or cerebellum. Prior low-grade glioma without prior RT, now with malignant progression are eligible
- Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted. Prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is >3 years
- Evidence of severe concurrent disease requiring treatment
- Patients treated with previous cranial or head/neck radiotherapy leading to significant radiation field overlap
- Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a Class D agent with the potential for teratogenic or abortifacient effects
- Nursing mothers declining to discontinue breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide
- Evidence of CSF dissemination (positive CSF cytology for malignancy or MRI findings consistent with CSF dissemination)
- Multifocal disease (>1 lobe of involvement) of discontiguous, contrast enhancing disease as seen on conventional MRI
- Known active malignancy as determined by treating medical and radiation oncologist
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring inpatient hospitalization or delay treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or compromise subject safety
- Patients unable to undergo MRI exams
- Patients with reproductive potential declining to use an effective contraceptive method during treatment are excluded from this study
Where in United States
- University of Iowa Department of Radiation OncologyIowa City, United States
About the trial
What the trial wants to find out
This clinical trial increases radiation to areas of the brain considered to be at risk for cancer. The at-risk areas are identified by a biological MRI scan. The study will look at side effects of the radiation and overall survival.
The group in the trial
- Radiation TherapyTreatment being tested
External beam radiation therapy delivered to target volume.
Treatment: External beam radiation therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma
- Record updated
- 9 September 2020